Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Multiplex Array Instrument

By Drug Discovery Trends Editor | March 9, 2009

BiOptix announced its four feature true multiplex array instrument with anticipated ship dates in the third quarter of 2009. This label free technology is expandable up to 96 features per array. Each array is present within a single flowcell that enables users to analyze complex mixtures for multiple biomolecules in a single sample injection. The technology has been performance tested using multiple biomolecular systems and chemistries, including proteins, nucleic acids, glycans, and whole pathogens.

BiOptix’ revolutionary yields the following benefits: 10x the sensitivity compared to the leading competition, true multiplex analysis exposing the sample to the entire array surface in a single flowcell, on-chip control for background effects such as non-specific binding, and user-customizable replaceable biochip that’s chemically modified outside the instrument and easily manipulated, according to BiOptix.

The design of the BiOptix 207B system addresses the needs of customers who are currently not well served by existing label free instrumentation. Entry markets include biopharma and low molecular weight drug development, kinetic analyses, antibody development and quality control, and process analysis. Future markets are in molecular diagnostics, including point of care and personalized medicine, which will benefit from the technology’s ease of use and speed to results.

Visit BiOptix at Pittcon 2009 at Booth #737

www.bioptix.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50